Is this the sort of deal Michelle might chase? Thinking more along the HIV front for outside interest in BIT225.
Johnson & Johnson ($JNJ) has deepened its ties to regenerative medicine outfit ViaCyte, handing the biotech $20 million in exchange for a future stake in the company and the right to acquire its in-development diabetes medication. Under the deal, J&J's cash buys it a note convertible into equity and an exclusive chance to acquire VC-01, ViaCyte's stem cell-derived treatment for Type 1 diabetes.
cash up front or take over is very near, page-13
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.0¢ |
Change
-0.003(9.09%) |
Mkt cap ! $27.06M | |||
| Open | High | Low | Value | Volume |
| 3.3¢ | 3.4¢ | 3.0¢ | $32.26K | 1.016M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 720804 | 3.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.1¢ | 30000 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| BIT (ASX) Chart |